Immunopotentiative composition
US9439962B2 · kind B2 · utility
52Cited by
31References
30Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 19, 2016 |
| Grant date | Sep 13, 2016 |
| Priority date | — |
| Expiry date | Jan 19, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods.The compositions of the present invention that inhibits the function of PD-1, PD-L1, PD-L2 are useful for cancer or infection treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.